322 related articles for article (PubMed ID: 30777124)
1. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC
Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124
[TBL] [Abstract][Full Text] [Related]
2. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.
Ladanyi M; Sanchez Vega F; Zauderer M
Genome Med; 2019 Mar; 11(1):18. PubMed ID: 30914057
[TBL] [Abstract][Full Text] [Related]
3. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
5. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
[TBL] [Abstract][Full Text] [Related]
6. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
9. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
10. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
Kittaneh M; Berkelhammer C
J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
[TBL] [Abstract][Full Text] [Related]
11. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M
Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601
[TBL] [Abstract][Full Text] [Related]
12. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
[TBL] [Abstract][Full Text] [Related]
13. Targeting BAP1: a new paradigm for mesothelioma.
Schunselaar LM; Zwart W; Baas P
Lung Cancer; 2017 Jul; 109():145-146. PubMed ID: 28342657
[TBL] [Abstract][Full Text] [Related]
14. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
[TBL] [Abstract][Full Text] [Related]
15. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
Pulford E; Huilgol K; Moffat D; Henderson DW; Klebe S
Dis Markers; 2017; 2017():1310478. PubMed ID: 29085180
[TBL] [Abstract][Full Text] [Related]
16. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.
Napolitano A; Pellegrini L; Dey A; Larson D; Tanji M; Flores EG; Kendrick B; Lapid D; Powers A; Kanodia S; Pastorino S; Pass HI; Dixit V; Yang H; Carbone M
Oncogene; 2016 Apr; 35(15):1996-2002. PubMed ID: 26119930
[TBL] [Abstract][Full Text] [Related]
17. Integrated Histogenetic Analysis Reveals
Bochtler T; Endris V; Reiling A; Leichsenring J; Schweiger MR; Klein S; Stögbauer F; Goeppert B; Schirmacher P; Krämer A; Stenzinger A
J Natl Compr Canc Netw; 2018 Jun; 16(6):677-682. PubMed ID: 29891518
[TBL] [Abstract][Full Text] [Related]
18. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
[TBL] [Abstract][Full Text] [Related]
20. Alterations in
Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
